Glioblastoma is widely recognized as one of the most formidable forms of cancer, with patients typically surviving only around 14 months after diagnosis. Current treatment strategies revolve around three main approaches: surgical removal, radiation therapy, and chemotherapy. However, the invasive nature of glioblastoma, which infiltrates healthy brain tissue, makes it extremely challenging to eliminate every cancerous cell. To monitor the potential return of the disease, patients commonly undergo MRI scans every three months, providing enough time for the tumor to potentially regrow.
In response to these challenges, the startup Coherence Neuro is introducing a novel treatment component: electrotherapy. They have created SOMA-1, a small neural implant that can be placed in the skull during tumor removal surgery. This AI-assisted device is engineered to continuously monitor the brain's electrical signals. If it identifies unusual patterns that could indicate tumor development, it sends targeted electrical signals to inhibit cancer cell growth and disrupt the tumor's interaction with surrounding healthy neurons.
The concept of utilizing electrical stimulation to manage glioblastoma is not entirely new, as the FDA-approved Optune system has been in use in the United States since 2011. However, the Optune system requires patients to wear a cumbersome cap with electrodes nearly all day, powered by a substantial battery. In contrast, SOMA-1 promises a more precise and patient-friendly alternative. Clinical trials involving human participants are anticipated to commence within the next 1.5 to 2 years.
The team behind the implant is optimistic about achieving results comparable to those seen in HIV treatment, aiming to transform glioblastoma from a terminal illness into a manageable chronic condition that individuals can live with for many years.
Informational material. 18+.
